



Biotech Daily

Tuesday January 18, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: IMUGENE UP 7%; ACTINOGEN DOWN 7%**
- * **UNIVERSAL BIOSENSORS LAUNCHES SENTIA MALIC ACID WINE TEST**
- * **RECCE: '150mg R327 SAFE, WELL TOLERATED'**
- * **RACE RECEIVES \$708k FEDERAL R&D TAX INCENTIVE**
- * **HERAMED REQUESTS 'COMMERCIAL LICENCE' TRADING HALT**
- * **SG HISCOCK TAKES 7.8% OF RESONANCE**
- * **COMPUMEDICS APPOINTS PAUL JENSZ DIRECTOR**
- * **OSTEOPORE TO LOSE CFO CARL RUNDE; NEW CFO WANTED**

MARKET REPORT

The Australian stock market fell 0.11 percent on Tuesday January 18, 2022, with the ASX200 down 8.5 points to 7,408.8 points. Thirteen of the Biotech Daily Top 40 stocks were up, 21 fell and six traded unchanged.

Imugene was the best, up 2.5 cents or 7.04 percent to 38 cents, with 44.6 million shares traded.

Cyclopharm, Impedimed, Kazia and Uscom climbed five percent or more; Neuren was up 3.6 percent; Atomo rose two percent; Dimerix, Immutep and Telix were up more than one percent; with Avita, Emvision, Resmed and Universal Biosensors up by less than one percent.

Actinogen led the falls, down one cent or 6.7 percent to 14 cents, with 3.45 million shares traded.

Micro-X and Oncosil lost more than five percent; Orthocell fell 4.1 percent; Amplia, Antisense, Clinuvel, Nanosonics, Nova Eye, Prescient, Pro Medicus, Proteomics and Resonance shed two percent or more; Alcidion, Cochlear, CSL, Cynata, Genetic Signatures, Polynovo and Volpara were down more than one percent; with Mesoblast, Next Science and Opthea down by less than one percent.

UNIVERSAL BIOSENSORS

Universal Biosensors says it has launched its Sentia Malic Acid Test wine testing device, with first sales and delivery expected by the end of this month.

Universal Biosensors said malic acid was an “important, time-consuming and difficult” test for winemakers, taking from 30 minutes to several hours and if sent to a third-party laboratory could take several days.

The company said its test measured malic acid in wine within 60 seconds.

Universal Biosensors said testing for malic acid was used for grape selection and in secondary fermentation, with concentration of the acid inversely related to grape ripeness. The company said that a winemaker might track and test the levels of malic acid in each variety of wine “many times during the secondary fermentation process” with an estimated 15 million tests a year, worldwide.

Universal Biosensors chief executive officer John Sharman said the launch of the Sentia’s Malic Acid Test was “an important achievement”.

“We have now the two most important tests used in winemaking being Free Sulphur and Malic Acid available on our platform,” Mr Sharman said.

Mr Sharman said that the combined market for the two tests was about \$270 million a year and “given the time saving, cost saving and accuracy of our Sentia device, we hope to win a significant market share”.

He said the company was ready to launch a Sentia Glucose Test and was finalizing the Sentia Fructose Test.

“We expect to launch Sentia Total Sugar’s Test into the global wine market in the coming weeks,” Mr Sharman said.

Universal Biosensors was up half a cent or 0.5 percent to 97.5 cents.

RECCE PHARMACEUTICALS

Recce says data from the second cohort of seven healthy males in the phase I trial of intravenous R327 synthetic antibiotic at 150mg showed safety and tolerability.

Earlier this month, Recce said an independent safety committee had approved a threefold dosing increase from 50 mg to 150mg after positive safety data from the first patient cohort of nine healthy males. (BD: Jan 16, 2022)

Today, Recce said that the elevated dose was well tolerated by all seven healthy male subjects in the second cohort, and that a third cohort was on-track to be dosed at 500mg this week.

The company said that R327 was safe and well tolerated at 150mg, “with no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters associated with R327”.

Recce was up four cents or 3.1 percent to \$1.34.

RACE ONCOLOGY

Race says it has received \$707,557 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Race said the rebate related to research and development expenditure for the year to June 30, 2021.

Race was unchanged at \$3.22.

HERAMED

Heramed has requested a trading halt pending an announcement regarding an Australian "licence agreement for the roll-out of the Heracare [product]".

Trading will resume on January 20, 2020 or on an earlier announcement.

Heramed was up 2.5 cents or 9.4 percent to 29 cents.

RESONANCE HEALTH

SG Hiscock & Co says it has increased its substantial share-holding in Resonance from 30,174,065 shares (6.55%) to 35,928,598 shares (7.8%).

The Melbourne-based SG Hiscock & Co said the shares were acquired between January 5 and 17, 2022, with the largest acquisition 706,585 shares for \$121,160 or 17.15 cents a share.

Resonance fell half a cent or 2.6 percent to 19 cents.

COMPUMEDICS

Compumedics says it has appointed Paul Jenz as a director, effective today, subject to a vote at its next shareholder meeting.

Compumedics said Mr Jenz was currently an executive director at Melbourne brokers PAC Partners Securities and had recently co-ordinated placements for Australian medical technology companies.

The company said Mr Jenz was currently the executive chair of the Agfood Fund investing in agriculture and food supply chains.

Compumedics said Mr Jenz would assist with corporate strategy, healthcare networks, emerging company relationships, finance and capital markets.

Compumedics was unchanged at 40 cents.

OSTEOPORE

Osteopore says chief financial officer Carl Runde has resigned "to pursue other opportunities" but will remain to finalize the year to December 31, 2021 results.

Osteopore said its Singapore-based finance operational support team would work with its external accounts team and it would recruiting a new chief financial officer.

Osteopore was unchanged at 28 cents.